MGUS and Myeloma: What’s the link?

Latest from the Blog

NEW COURSE: Managing Physical Effects

NEW COURSE: Managing Physical Effects

Tuesday 5th January 2021 We are delighted to announce that the new Managing Physical Effects course is now available on GatewayC. According to Macmillan, at least 1 in 4 patients will experience consequences of their cancer or treatment that affect their quality of...

read more
GatewayC’s top tips from 2020

GatewayC’s top tips from 2020

Monday 4th January 2021 2020 certainly provided challenges and many new learning opportunities for primary care professionals across England. With this in mind, we have rounded up some of our most popular 2020 tips. Take a look below! COVID-19 and neutropenic sepsis...

read more

Related Posts

Meet the specialists: improving early diagnosis Q&A

Meet the specialists: improving early diagnosis Q&A

Friday 27th November 2020 Missed our free GatewayC webinar on Improving Early Diagnosis? Watch our recording here. In this webinar, GatewayC met Dr Anthony Cunliffe, Joint National Lead Macmillan GP Adviser, and Dr Ben Noble, East Midlands Cancer Alliance and Cancer...

read more

MGUS is a benign condition which does not usually require treatment. However, a small number of patients diagnosed with MGUS will go on to develop myeloma.

Understanding MGUS

Monoclonal gammopathy of undetermined significance (MGUS) is a benign condition characterised by the presence of paraproteins in the blood and/or urine. It doesn’t cause symptoms or require treatment and is usually only diagnosed when patients are investigated for other issues.

While most people with MGUS will not see an effect on their general health, about 1% of patients with MGUS will go on to develop myeloma each year.

Specialist viewpoint

The GatewayC Myeloma – Early Diagnosis course explores MGUS and its relationship with Myeloma in greater detail. GatewayC’s Cancer Lead GP, Dr. Sarah Taylor discusses the significance of this pre-malignant condition with Dr. Neil Rabin, Consultant Haematologist at University College London Hospitals and North Middlesex University Hospital NHS Trust.

What does Myeloma UK say about MGUS and Myeloma ?

MGUS is a condition which resembles myeloma due to the presence of abnormal plasma cells in the bone marrow and paraprotein in the blood and/or urine, but at much lower levels than in myeloma.

Each year around one in 100 MGUS patients will be diagnosed with myeloma and will need treatment. MGUS usually remains stable for many years without progressing to myeloma. Data suggests that if MGUS remains stable for two years then, on average, it will remain stable for 10 years before there is progression to myeloma.*

Cancer Key:

The presence of paraproteins in a patient’s blood or urine doesn’t necessarily mean they have myeloma and could be indicative of MGUS. However, it is important that these patients are sent to a haematologist, so that they can be appropriately investigated and be given advice on what symptoms to look out for.

Find out more: visit the GatewayC Myeloma – Early Diagnosis course here.

Keep up to date: Twitter | Facebook | LinkedIn

* Information from Myeloma UK – MGUS. See link here.

Latest from the Blog

NEW COURSE: Managing Physical Effects

NEW COURSE: Managing Physical Effects

Tuesday 5th January 2021 We are delighted to announce that the new Managing Physical Effects course is now available on GatewayC. According to Macmillan, at least 1 in 4 patients will experience consequences of their cancer or treatment that affect their quality of...

read more
GatewayC’s top tips from 2020

GatewayC’s top tips from 2020

Monday 4th January 2021 2020 certainly provided challenges and many new learning opportunities for primary care professionals across England. With this in mind, we have rounded up some of our most popular 2020 tips. Take a look below! COVID-19 and neutropenic sepsis...

read more

Related Posts

Meet the specialists: improving early diagnosis Q&A

Meet the specialists: improving early diagnosis Q&A

Friday 27th November 2020 Missed our free GatewayC webinar on Improving Early Diagnosis? Watch our recording here. In this webinar, GatewayC met Dr Anthony Cunliffe, Joint National Lead Macmillan GP Adviser, and Dr Ben Noble, East Midlands Cancer Alliance and Cancer...

read more